150 related articles for article (PubMed ID: 33365356)
1. Efficacy and Safety of Eravacycline in Obese Patients: A Post Hoc Analysis of Pooled Data From the IGNITE1 and IGNITE4 Clinical Trials.
Asempa TE; Izmailyan S; Lawrence K; Nicolau DP
Open Forum Infect Dis; 2020 Dec; 7(12):ofaa548. PubMed ID: 33365356
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and Tolerability of Eravacycline in Bacteremic Patients with Complicated Intra-Abdominal Infection: A Pooled Analysis from the IGNITE1 and IGNITE4 Studies.
Felice VG; Efimova E; Izmailyan S; Napolitano LM; Chopra T
Surg Infect (Larchmt); 2021 Jun; 22(5):556-561. PubMed ID: 33201771
[No Abstract] [Full Text] [Related]
3. IGNITE4: Results of a Phase 3, Randomized, Multicenter, Prospective Trial of Eravacycline vs Meropenem in the Treatment of Complicated Intraabdominal Infections.
Solomkin JS; Gardovskis J; Lawrence K; Montravers P; Sway A; Evans D; Tsai L
Clin Infect Dis; 2019 Aug; 69(6):921-929. PubMed ID: 30561562
[TBL] [Abstract][Full Text] [Related]
4. Phase 2, randomized, double-blind study of the efficacy and safety of two dose regimens of eravacycline versus ertapenem for adult community-acquired complicated intra-abdominal infections.
Solomkin JS; Ramesh MK; Cesnauskas G; Novikovs N; Stefanova P; Sutcliffe JA; Walpole SM; Horn PT
Antimicrob Agents Chemother; 2014; 58(4):1847-54. PubMed ID: 24342651
[TBL] [Abstract][Full Text] [Related]
5. Assessing the Efficacy and Safety of Eravacycline vs Ertapenem in Complicated Intra-abdominal Infections in the Investigating Gram-Negative Infections Treated With Eravacycline (IGNITE 1) Trial: A Randomized Clinical Trial.
Solomkin J; Evans D; Slepavicius A; Lee P; Marsh A; Tsai L; Sutcliffe JA; Horn P
JAMA Surg; 2017 Mar; 152(3):224-232. PubMed ID: 27851857
[TBL] [Abstract][Full Text] [Related]
6. Eravacycline: a new treatment option for complicated intra-abdominal infections in the age of multidrug resistance.
Solomkin JS; Sway A; Lawrence K; Olesky M; Izmailyan S; Tsai L
Future Microbiol; 2019 Oct; 14():1293-1308. PubMed ID: 31570004
[No Abstract] [Full Text] [Related]
7. The Efficacy and Safety of Eravacycline in the Treatment of Complicated Intra-Abdominal Infections: A Systemic Review and Meta-Analysis of Randomized Controlled Trials.
Lan SH; Chang SP; Lai CC; Lu LC; Chao CM
J Clin Med; 2019 Jun; 8(6):. PubMed ID: 31212991
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of Eravacycline: A Novel Fluorocycline.
Alosaimy S; Abdul-Mutakabbir JC; Kebriaei R; Jorgensen SCJ; Rybak MJ
Pharmacotherapy; 2020 Mar; 40(3):221-238. PubMed ID: 31944332
[TBL] [Abstract][Full Text] [Related]
9. Eravacycline: A Review in Complicated Intra-Abdominal Infections.
Scott LJ
Drugs; 2019 Feb; 79(3):315-324. PubMed ID: 30783960
[TBL] [Abstract][Full Text] [Related]
10. The efficacy and safety of eravacycline compared with current clinically common antibiotics in the treatment of adults with complicated intra-abdominal infections: A Bayesian network meta-analysis.
Meng R; Guan X; Sun L; Fei Z; Li Y; Luo M; Ma A; Li H
Front Med (Lausanne); 2022; 9():935343. PubMed ID: 36186801
[TBL] [Abstract][Full Text] [Related]
11. Effect of body mass index on treatment of complicated intra-abdominal infections in hospitalized adults: comparison of ertapenem with piperacillin-tazobactam.
Zakrison TL; Hille DA; Namias N
Surg Infect (Larchmt); 2012 Feb; 13(1):38-42. PubMed ID: 22217196
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of eravacycline: A meta-analysis.
Eljaaly K; Ortwine JK; Shaikhomer M; Almangour TA; Bassetti M
J Glob Antimicrob Resist; 2021 Mar; 24():424-428. PubMed ID: 33621690
[TBL] [Abstract][Full Text] [Related]
13. Efficacy, safety, and tolerability of a ready-to-drink bowel preparation in overweight and obese adults: subanalysis by body mass index from a phase III, assessor-blinded study.
Hookey L; Bertiger G; Johnson KL; Boules M; Ando M; Dahdal DN
Therap Adv Gastroenterol; 2020; 13():1756284820910050. PubMed ID: 32313553
[TBL] [Abstract][Full Text] [Related]
14. Bariatric surgery: an evidence-based analysis.
Medical Advisory Secretariat
Ont Health Technol Assess Ser; 2005; 5(1):1-148. PubMed ID: 23074460
[TBL] [Abstract][Full Text] [Related]
15. Review of Eravacycline, a Novel Fluorocycline Antibacterial Agent.
Zhanel GG; Cheung D; Adam H; Zelenitsky S; Golden A; Schweizer F; Gorityala B; Lagacé-Wiens PR; Walkty A; Gin AS; Hoban DJ; Karlowsky JA
Drugs; 2016 Apr; 76(5):567-88. PubMed ID: 26863149
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of rimonabant for improvement of multiple cardiometabolic risk factors in overweight/obese patients: pooled 1-year data from the Rimonabant in Obesity (RIO) program.
Van Gaal L; Pi-Sunyer X; Després JP; McCarthy C; Scheen A
Diabetes Care; 2008 Feb; 31 Suppl 2():S229-40. PubMed ID: 18227491
[TBL] [Abstract][Full Text] [Related]
17. Actual versus ideal body weight dosing of sugammadex in morbidly obese patients offers faster reversal of rocuronium- or vecuronium-induced deep or moderate neuromuscular block: a randomized clinical trial.
Horrow JC; Li W; Blobner M; Lombard J; Speek M; DeAngelis M; Herring WJ
BMC Anesthesiol; 2021 Feb; 21(1):62. PubMed ID: 33639839
[TBL] [Abstract][Full Text] [Related]
18. Safety and Efficacy of High-Dose Unfractionated Heparin for Prevention of Venous Thromboembolism in Overweight and Obese Patients.
Joy M; Tharp E; Hartman H; Schepcoff S; Cortes J; Sieg A; Mariski M; Lee Y; Murphy M; Ranjbar G; Sharaf S; Yau G; Choi HA; Samuel S
Pharmacotherapy; 2016 Jul; 36(7):740-8. PubMed ID: 27265806
[TBL] [Abstract][Full Text] [Related]
19. Eravacycline: The Tetracyclines Strike Back.
Heaney M; Mahoney MV; Gallagher JC
Ann Pharmacother; 2019 Nov; 53(11):1124-1135. PubMed ID: 31081341
[No Abstract] [Full Text] [Related]
20. Do acute hospitalised patients in Australia have a different body mass index to the general Australian population: a point prevalence study?
Dennis DM; Carter V; Trevenen M; Tyler J; Perrella L; Lori E; Cooper I
Aust Health Rev; 2018 Apr; 42(2):121-129. PubMed ID: 28225703
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
